Close Menu

Pacific Biosciences

The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.

News items for the in vitro diagnostics industry for the week of August 10, 2020.

PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.

Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.

The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market.